

**University of Texas Health Science Center at San Antonio
Institutional Biosafety Committee (IBC)
Microsoft Teams MINUTES OF MEETING
July 08, 2025**

Members attending the meeting: Bieniek, Kevin; Chatterjee, Bandana; Chen, Ching-Kang Jason; Elliott, James; Gould, Georgianna; Martinez-Sobrido, Luis; Mishra, Bibhuti; Paukert, Martin; Prewit, Egle; Salamango, Daniel; Xiang, Yan; Yeh, Chih-Ko; Bloodworth, Rebecca; Macias, Dorothy (alternate for Charlton, Michael - voting)

Guests Present: Rincon, Erica; Melendez, Griselda; Barlett, Emily; Vasquez, Rebecca.

Absent members: Charlton, Michael; Burgin, Tiffani; Dallas, Steven; Gauduin, Marie Claire; Ginsburg, Brett; Ko, Jisook; Shio, Yuzuru; Vogel, Kristine; Wiederhold, Nathan.

1. Panel Chair Announcement

The meeting was called to order at 11:00 a.m. by the IBC Chair, Dr. Yan Xiang. A quorum was established.

2. Confidentiality of Panel Proceedings and Conflict of Interest

The members of the panel and the persons employed by the panel shall maintain the confidentiality of the panel's proceedings unless such information is already made available to the public. The Parties shall maintain the confidentiality of the panel's hearings, deliberations, and initial report, and all written submissions to, and communications with, the panel.

Board Members will be reminded of their responsibility to declare any conflicts of interest prior to the discussion of an agenda item. Members will be reminded that in the event they have a conflict of interest (e.g. a member of the research team or is supervised by a member of the research team), the Member with a conflict may be in the meeting room to provide information requested by the IBC but will be asked to leave the meeting room before the final discussion and voting on the protocol with which the IBC Member has a conflict.

3. Approval of minutes from the previous meeting

The Committee approved the minutes as written from the June 10, 2025, IBC meeting.

Approved (11 voted to approve, 0 opposed, 0 abstained)

4. Review of Approved Protocols- The spreadsheet of approved protocols will be sent out for review in August 2025.

5. Old Business – Dr. Svatek's IBC Clinical Protocol was discussed and approved with stipulation.

6. Educational Items – None

7. Occupational Medicine- None

8. Other –Both of the FACs SOPs were reviewed and approved. Also, the use of SARS-CoV-2 at BSL-2+ containment was revisited and it was agreed upon that a SARS-CoV2 SOP needs to be written.

9. Review of EHS Assistant-

10. Meeting Reminder

The next meeting will be held on August 12, 2025.

Protocols for Review

11. Presentation, Discussion, and Voting on a Renewal Protocol:

Protocol ID: 0000020136

Principal Investigator: Sprague, Eugene; Medicine-Cardiology

Title: N/A

Review Type: Full Review

Form Type: Renewal

Approved (11 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with THP-1 and HAEC at BSL-2 containment.

Protocol does not include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

12. Presentation, Discussion, and Voting on an Initial Protocol:

Protocol ID: 0000020135

Principal Investigator: Lin, Li-Ling; Molecular Medicine

Title: The PAI-1/LRP1 Axis as a Therapeutic Target for Immunosuppression in Endometrial Cancer.

Review Type: Full Review

Form Type: Initial

Approved (11 voted to approve, 0 opposed, 0 abstained)

Initial application to work with shRNA and Lentivirus at BSL-2 containment. Work with mouse cell lines (MECPR-GFP), vector (pLKO.1 puro), and E. coli at BSL-1 containment.

In vivo:

Work with shRNA in mice at ABSL-2 containment.

IACUC# 202500000069

Protocol does include the use of recombinant DNA

This protocol was approved as written.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1
Cloning and vector construction in bacteria and yeasts. III-E, III-F
Use of recombinant or synthetic nucleic acid molecules for detection purposes (e.g. probes) III-F
Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F
Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4

13. Presentation, Discussion, and Voting on a Renewal Protocol:

Protocol ID: 0000020037

Principal Investigator: Klykov, Oleg; Biochemistry & Structural Biology

Title: N/A

Review Type: Full Review

Form Type: Renewal

Approved (11 voted to approve, 0 opposed, 0 abstained)

Renewal application, to work with Human brain tissue, mouse brain tissue, replication incompetent lentiviral-GRIA2-mouse-GluA2 and vectors (AAV5-CAMKII-(hm3dp)-tdTomato, AAV5-CAMII-tdTomato) at BSL-2 containment. Work with AAV at BSL-1 containment. Work with transgenic mouse strains (GluA2-StrepII, eGFP-PSD95, mScarlett-VGLUT1) at ABSL-1 containment. IACUC# IPROTO2024000000480
Protocol does include the use of recombinant DNA.

This protocol was approved with clarification.

1. The committee has requested clarification on how samples will be transported to the core facilities.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1
Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1
Cloning and vector construction in bacteria and yeasts. III-E, III-F
Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4
Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3
Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4

14. Presentation, Discussion, and Voting on a Renewal Protocol:

Protocol ID: 0000020036

Principal Investigator: Loverde, Philip; Biochemistry & Structural Biology

Title: None

Review Type: Full Review

Form Type: Renewal

Approved (11 voted to approve, 0 opposed, 0 abstained)

Renewal application, to work with Schistosoma species, Retrovirus, FL TSP-2mRNA, Loop2 mRNA, Recombinant Loop2 mRNA, SS Loop2 mRNA, GPILoop2 mRNA, sm-TSP-2 recombinant Protein, human cell line HELA at BSL-2 containment. Work with E. coli and vectors (pcDNA3.1, pUC18/19, pMAL, pET, pCITE, PCRII, pGEX4T, pCoHYGRO, VR1020, VR1055, pcDNA-AMP, pCMV-GST, and LNHX) at BSL-1 containment.

In vivo:

Work with Schistosoma species, Loop2 mRNA, Recombinant Loop2 mRNA, SS Loop2 mRNA, FL TSP-2mRNA, GPILoop2 mRNA, and sm-TSP-2 recombinant Protein in hamsters and mice at ABSL-2 containment.

IACUC# 1187, #20110087AR

Protocol does include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

Use of or the cloning of genes from, or into a Risk Group 2, 3, 4 or restricted agent. III-D-1, 2

Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1


Cloning and vector construction in bacteria and yeasts. III-E, III-F

Use of recombinant or synthetic nucleic acid molecules for detection purposes (e.g. probes) III-F


Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F

Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4

Adjourn: The meeting adjourned at 12:40 P.M.



Dr. Yan Xiang
Institutional Biosafety Committee Chair
University of Texas Health San Antonio



Dorothy Macias
Recorder, Institutional Biosafety Committee
University of Texas Health San Antonio

dam